New drug combo aims to prevent deadly bowel blockages in ovarian cancer
NCT ID NCT07648745
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel tears or holes. If the cancer worsened, patients could switch to a different drug combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cediranib (a drug that blocks blood vessel growth) combined with paclitaxel chemotherapy
What this could lead to
If successful, this could show that cediranib can be used safely in women with advanced ovarian cancer who are at risk of bowel obstruction, potentially offering a treatment option where few exist.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group. The main goal is safety, not effectiveness, so it may not lead to a proven treatment. There is also a risk of serious side effects like bowel perforation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom